Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Chemoradiotherapy (CRT) + Anti-Epidermal growth factor receptor (EGFR; ErbB-1; HER1) monoclonal antibodies & Nasopharyngeal carcinoma (NPC) / Nasopharynx cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Adding anti-EGFR monoclonal antibodies to standard treatment for nasopharyngeal carcinoma may help. This includes using them with radiotherapy or chemoradiotherapy. Some studies show benefits. However, using CRT with cetuximab or nimotuzumab compared to CRT alone has not always improved survival rates in past data.
Mao et al. 2019 Clin Otolaryngol 44(4): 572-580

References (Sources)

Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression
Mao et al. 2019 Clin Otolaryngol 44(4): 572-580

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Chemoradiotherapy (CRT) + Anti-Epidermal growth factor receptor (EGFR; ErbB-1; HER1) monoclonal antibodies & Nasopharyngeal carcinoma (NPC) / Nasopharynx cancer

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat